tiprankstipranks
Advertisement
Advertisement

ATRA Stock Latest News

Atara Biotherapeutics Faces Securities Lawsuit After FDA Setbacks and Sharp Stock Declines Tied to Tabelecleucel 
Class ActionAtara Biotherapeutics Faces Securities Lawsuit After FDA Setbacks and Sharp Stock Declines Tied to Tabelecleucel 
11d ago
ATRA
Atara Biotherapeutics Faces Federal Securities Lawsuit Over Alleged Misstatements About Drug Approval Prospects
PremiumClass Action
Atara Biotherapeutics Faces Federal Securities Lawsuit Over Alleged Misstatements About Drug Approval Prospects
1M ago
ATRA
Atara Biotherapeutics files to sell 400K shares of common stock for holders
PremiumThe Fly
Atara Biotherapeutics files to sell 400K shares of common stock for holders
1M ago
ATRA
Atara provides update on tabelecleucel biologics license application
PremiumThe Fly
Atara provides update on tabelecleucel biologics license application
2M ago
ATRA
Atara Plans FDA Type A Meeting on EBVALLO
PremiumCompany Announcements
Atara Plans FDA Type A Meeting on EBVALLO
2M ago
8K
ATRA
Atara, Pierre Fabre seek FDA meeting on EBVALLO
PremiumCompany AnnouncementsAtara, Pierre Fabre seek FDA meeting on EBVALLO
2M ago
8K
ATRA
Atara Biotherapeutics partner submits Type A meeting request to FDA
Premium
The Fly
Atara Biotherapeutics partner submits Type A meeting request to FDA
2M ago
ATRA
ATRA Earnings this Week: How Will it Perform?
Premium
Pre-Earnings
ATRA Earnings this Week: How Will it Perform?
2M ago
ATRA
Atara Biotherapeutics Extends Royalty Milestone, Issues Warrant
PremiumCompany Announcements
Atara Biotherapeutics Extends Royalty Milestone, Issues Warrant
2M ago
8K
ATRA
Atara Biotherapeutics amends HealthCare Royalty purchase, sale agreement
PremiumThe Fly
Atara Biotherapeutics amends HealthCare Royalty purchase, sale agreement
2M ago
ATRA
Tabelecleucel’s Phase 3 EBV+ PTLD Trial Progress Signals Continued Potential for Atara Biotherapeutics
PremiumCompany Announcements
Tabelecleucel’s Phase 3 EBV+ PTLD Trial Progress Signals Continued Potential for Atara Biotherapeutics
3M ago
ATRA
Atara Biotherapeutics downgraded to Hold from Buy at Canaccord (earlier)
PremiumThe Fly
Atara Biotherapeutics downgraded to Hold from Buy at Canaccord (earlier)
3M ago
ATRA
FDA Rejects Atara’s EBVALLO BLA, Commercial Path Uncertain
PremiumCompany AnnouncementsFDA Rejects Atara’s EBVALLO BLA, Commercial Path Uncertain
4M ago
8K
ATRA
FDA says unable to approve Atara Biotherapeutics Ebvallo BLA in present form
Premium
The Fly
FDA says unable to approve Atara Biotherapeutics Ebvallo BLA in present form
4M ago
ATRA
Morning News Wrap-Up: Thursday’s Biggest Stock Market Stories!
Premium
Market News
Morning News Wrap-Up: Thursday’s Biggest Stock Market Stories!
4M ago
F
AEP
Atara Biotherapeutics Stock (ATRA) Jumps as FDA Decision on Viral Therapy Nears
PremiumMarket News
Atara Biotherapeutics Stock (ATRA) Jumps as FDA Decision on Viral Therapy Nears
4M ago
ATRA
Atara revises tab-cel commercialization milestones with Pierre Fabre
PremiumCompany Announcements
Atara revises tab-cel commercialization milestones with Pierre Fabre
4M ago
8K
ATRA
Atara Biotherapeutics price target raised to $25 from $17 at Canaccord
PremiumThe Fly
Atara Biotherapeutics price target raised to $25 from $17 at Canaccord
4M ago
ATRA
ATRA Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-Earnings
ATRA Earnings Report this Week: Is It a Buy, Ahead of Earnings?
5M ago
ATRA
Atara Biotherapeutics price target raised to $18 from $16 at Mizuho
PremiumThe FlyAtara Biotherapeutics price target raised to $18 from $16 at Mizuho
5M ago
ATRA
Atara Biotherapeutics price target raised to $140 from $131 at Mizuho
Premium
The Fly
Atara Biotherapeutics price target raised to $140 from $131 at Mizuho
5M ago
ATRA
Potential FDA Approval of Atara’s Tab-cel Therapy: A Game-Changer for Future Growth and CAR T Program Revitalization
Premium
Ratings
Potential FDA Approval of Atara’s Tab-cel Therapy: A Game-Changer for Future Growth and CAR T Program Revitalization
6M ago
ATRA

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >